This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Arcoxia

Merck & Co., Inc.

Drug Names(s): etoricoxib, MK-663, MK-0663

Description: Arcoxia is Merck's second nonsteroidal anti-inflammatory drug that exhibits anti-inflammatory, analgesic, and antipyretic activities. It inhibits prostaglandin synthesis by selectively inhibiting cyclooxygenase-2 (COX-2).

Deal Structure: Merck & Grunenthal
In May 2014, Grnenthal announced the signing of an exclusive promotion and distribution agreement with MSD covering etoricoxib. This agreement covers Germany, UK, France, Belgium, Luxemburg, Ireland, and Austria. Etoricoxib is marketed under the brand name Arcoxia in these markets.

Partners: Grünenthal GmbH


Arcoxia News

Pink Sheet Drug Safety

Pink Sheet Merck Arcoxia NDA


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug